Marken Expands Kit-Building Ops in Singapore to Meet Client Demand

By Zachary Brennan

- Last updated on GMT

Marken Expands Kit-Building Ops in Singapore to Meet Client Demand

Related tags: Germany

Due to growing client demand, Marken will expand its kit-building operations in Singapore to increase production by about 10,000 kits per month.

Marken currently produces 15,000 kits per month at the site and distributes more than 350,000 kits annually to investigator sites around the world.

We currently produce basic as well as PK/PD Kits in Singapore​,” Gerit Offenhauser, SVP of clinical distribution, told Outsourcing-Pharma.com. “As part of this expansion, Marken invested significantly into the IT systems which host both our client-specific kit systems as well as our own kit manufacturing software​.”

The new infrastructure will help Marken meet client demands, particularly in prelabelled blood collection tubes and bulk supplies, Offenhauser said.

Marken has experienced increased demand and need for Singapore-based services from not only the local Asia client base, but also from US and European life science organizations who are also expanding in the APAC region​,” Offenhauser added.

Although he did not disclose the amount invested in the site, he said this is phase one of what could be a two-phase expansion for “scalable production that can be increased as needed​.”

Marken also has kit-building operations in Hamburg, Germany, and is evaluating an additional kit-building facility in either Miami or Brazil in the coming months.

Since our research and client communications indicate a growing need specifically for Latin America, and Brazil in particular, that location will be a focus for the next expansion phase​,” Offenhauser said.

Related news

Show more

Related products

show more

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars